Home
About
Overview
Sharing Data
ORCID
Help
History (1)
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping.
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping. Cancer Treat Rev. 2020 Jul; 87:102022.
View in:
PubMed
subject areas
Animals
Carcinoma, Non-Small-Cell Lung
Exons
Humans
Lung Neoplasms
Protein Kinase Inhibitors
Proto-Oncogene Proteins c-met
Randomized Controlled Trials as Topic
Xenograft Model Antitumor Assays
authors with profiles
Ravi Salgia